Cohance Lifesciences Stock Jumps Over 2% Despite Poor Q1 Earnings; Here's Why

Shares of Cohance Lifesciences advanced in trade even after weak Q1 results, with the market taking comfort from the absence of data integrity observations in the USFDA inspection.